Koistinen H A, Dusserre E, Ebeling P, Vallier P, Koivisto V A, Vidal H
Department of Medicine, Division of Geriatrics, Helsinki University Central Hospital, Helsinki, Finland.
Diabetes Metab Res Rev. 2000 Sep-Oct;16(5):364-9. doi: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr148>3.0.co;2-c.
Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been suggested to be a part of the insulin resistance syndrome, and recent data suggest that adipose tissue participates in the production of PAI-1. We examined the expression and insulin regulation of subcutaneous adipose tissue PAI-1 mRNA and its relationship to insulin sensitivity.
A cross-sectional study involving five lean (60.0+/-3.1 years, BMI 23.5+/-0.5 kg/m(2)) and six obese nondiabetic men (56.0+/-3.1 years, BMI 30.4+/-0.7 kg/m(2)), and six obese Type 2 diabetic men (61.4+/-3.2 years, BMI 31.8+/-1.0 kg/m(2)).
Subcutaneous adipose tissue PAI-1 mRNA and insulin sensitivity were quantified using RT-competitive PCR and euglycemic hyperinsulinemic clamp technique, respectively.
Subcutaneous adipose tissue PAI-1 mRNA levels were higher in obese nondiabetic and Type 2 diabetic men than in lean nondiabetic men. PAI-1 mRNA levels decreased in the three groups during a 240-min euglycemic hyperinsulinemic clamp (P<0.05 for all groups), and a similar reduction was observed during a 240-min saline control study indicating that adipose tissue PAI-1 gene expression has diurnal variation and is not acutely controlled by hyperinsulinemia. The basal PAI-1 mRNA levels correlated positively with BMI, and waist-to-hip ratio; and negatively with whole-body glucose disposal rate in nondiabetic men.
Subcutaneous adipose tissue PAI-1 mRNA expression is increased in obese nondiabetic or in Type 2 diabetic men. Subcutaneous adipose tissue PAI-1 mRNA expression is increased in proportion to visceral obesity and to the level of whole-body insulin resistance. Subcutaneous adipose tissue PAI-1 mRNA expression is not acutely regulated by insulin, and it is subject to a diurnal variation.
血浆纤溶酶原激活物抑制剂-1（PAI-1）水平升高被认为是胰岛素抵抗综合征的一部分，最近的数据表明脂肪组织参与PAI-1的产生。我们研究了皮下脂肪组织PAI-1 mRNA的表达及胰岛素调节作用及其与胰岛素敏感性的关系。
一项横断面研究，纳入5名瘦男性（60.0±3.1岁，体重指数23.5±0.5 kg/m²）、6名肥胖非糖尿病男性（56.0±3.1岁，体重指数30.4±0.7 kg/m²）和6名肥胖2型糖尿病男性（61.4±3.2岁，体重指数31.8±1.0 kg/m²）。
分别采用逆转录竞争聚合酶链反应和正常血糖高胰岛素钳夹技术对皮下脂肪组织PAI-1 mRNA和胰岛素敏感性进行定量。
肥胖非糖尿病和2型糖尿病男性的皮下脂肪组织PAI-1 mRNA水平高于瘦非糖尿病男性。在240分钟的正常血糖高胰岛素钳夹期间，三组的PAI-1 mRNA水平均下降（所有组P<0.05），在240分钟的生理盐水对照研究中也观察到类似的下降，表明脂肪组织PAI-1基因表达具有昼夜变化，不受高胰岛素血症的急性控制。基础PAI-1 mRNA水平与体重指数和腰臀比呈正相关，与非糖尿病男性的全身葡萄糖处置率呈负相关。
肥胖非糖尿病或2型糖尿病男性的皮下脂肪组织PAI-1 mRNA表达增加。皮下脂肪组织PAI-1 mRNA表达与内脏肥胖和全身胰岛素抵抗水平成比例增加。皮下脂肪组织PAI-1 mRNA表达不受胰岛素的急性调节，且具有昼夜变化。
